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Abstract
Δ8-Tetrahydrocannabinol (Δ8THC) is marketed in many US states as ‘legal weed’. Concerns exist relating to class-wide genotoxic
cannabinoid effects. We conducted an epidemiological investigation of Δ8THC-related genotoxicity expressed as 57 congenital anomaly
(CA) rates (CARs) in the USA. CARs were taken from the Centers for Disease Control, Atlanta, Georgia. Drug exposure data were taken
from the National Survey of Drug Use and Health, with a response rate of 74.1%. Ethnicity and income data were taken from the US Census Bureau. National cannabinoid exposure was taken from Drug Enforcement Agency publications and multiplied by state cannabis
use data to derive state-based estimates of Δ8THC exposure. At bivariate continuous analysis, Δ8THC was associated with 23 CAs
on raw CA rates, 33 CARs after correction for early termination for anomaly estimates and 41 on a categorical analysis comparing
the highest and lowest exposure quintiles. At inverse probability weighted multivariable additive and interactive models lagged to 0,
2 and 4 years, Δ8THC was linked with 39, 8, 4 and 9 CAs. Chromosomal, cardiovascular, gastrointestinal, genitourinary, limb, central nervous system (CNS) and face systems were particularly affected. The minimum E-values ranged to infinity. Both the number of
anomalies implicated and the effect sizes demonstrated were much greater for Δ8THC than for tobacco and alcohol combined. Δ8THC
appears epidemiologically to be more strongly associated with many CAs than for tobacco and alcohol and is consistent with a cannabinoid class genotoxic/epigenotoxic effect. Quantitative causality criteria were fulfilled, and causal relationships either for Δ8THC or for
cannabinoid/s, for which it is a surrogate marker, may be in operation.

Key words: cannabis; cannabinoid; cancer; mutagenesis; oncogenesis; genotoxicity; epigenotoxicity; chromosomal toxicity; Δ8THC;
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Introduction
Δ8-Tetrahydrocannabinol (Δ8THC) is increasingly being marketed
in many parts of USA often under the rubric of ‘legal weed’ [1].
Whilst its effects are generally said to be milder than those of
Δ9THC [2], its effects in overdose are virtually identical, with
reports of sedation, vomiting, drowsiness, confusion, erratic
behaviour and psychotic episodes becoming so common that both
the Centers for Disease Control (CDC) and the Food and Drug
Administration (FDA) have recently issued cautionary warnings
related to its use [3, 4].
Δ8THC is made artificially from Δ9THC usually by acidification
and isomerization, so the double bond on carbon 9 of the C-ring
shifts across to the eighth carbon atom on this ring [2]. Δ8THC
is commonly extracted from low THC hemp residues remaining
after hemp processing. In this sense, therefore, the new wave
of Δ8THC poisonings coming to the attention of the CDC and
the FDA represents a nascent but man-made epidemic, which is

therefore fundamentally different from the previous popularization of cannabis use to sweep USA.
One of the more concerning effects of cannabinoid compounds is their genotoxicity, which has been a focus of research
efforts for several decades. As long ago as 1969, severe effects
of prenatal cannabinoid exposure on a range of birth defects
were described, including exomphalos, foetal loss and resorption, encephalocele, spina bifida and phocomelia, in rabbits
and rodents [5–7]. This report was later confirmed by a report
that 21 congenital anomalies (CAs) were elevated in humans
after prenatal cannabis exposure in Hawaii [8], and this has
since been confirmed by similar studies from Canada, Australia,
Colorado and USA [9–14]. The commonest cancer of early childhood acute lymphoid leukaemia and total pediatric cancers
were both shown recently to be related to cannabis, Δ9THC
and cannabigerol, thereby strongly implicating intergenerational
transmission of inheritable genotoxicity and/or epigenotoxicity

Received 7 December 2021; revised 13 May 2022; accepted 16 May 2022
© The Author(s) 2022. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Downloaded from https://academic.oup.com/eep/article/8/1/dvac012/6586812 by Serials Acquisitions Edith Cowan University, Library-Level 2 user on 16 September 2022

Congenital anomaly epidemiological correlates of
Δ8THC across USA 2003–16: panel regression and
causal inferential study

Methods
Data
Data on the rates of 62 CAs in each state of the USA were taken
from published reports of the National Birth Defects Prevention
Network (NBDPN) sponsored by the CDC, Atlanta, Georgia [47].

These reports are a collation of usually 5-year incidence rate data
averaged across all races from 2003–07 to 2012–16, which are the
most recent reports available at the time of writing. Data are based
on reports to state registries made after birth and are based on
ICD-9 codes. For each report, the mid-year of the reporting period
was taken as the reference year for the purposes of this analysis.
Data for Montana, Pennsylvania, Wyoming, Alabama, Idaho and
South Dakota were not available. The nomenclature for orofacial
clefts (cleft lip alone, cleft lip with and without cleft palate, cleft lip
and cleft palate and cleft palate alone) changed during the study
period, so all four CAs have been combined together for analytical purposes as orofacial clefts. Similarly, the nomenclature for
arm, leg and limb reduction changed across the reporting period,
so these were all combined into a single category of limb reduction
defects for analysis. These adjustments left 57 CAs for analysis. At
present. NBDPN reports are based on 45 anomalies, and these have
changed across time.
Average annual drug use data were taken from the Restricted
Data Access Scheme of the National Survey of Drug Use and
Health conducted annually by the Substance Abuse and Mental Health Services Administration [48]. This is an annual survey
conducted nationally, which is well established to be the representative of the non-institutionalized US adult population. The
survey has a response rate of 74.1% [48]. The substances of interest were last-month cigarettes use, last-month alcohol abuse or
dependence [denoted as Alcohol Use Disorder (AUD)], last-month
cannabis use and last-year non-medical use of narcotic analgesics
or cocaine. Ethnicity and income data were taken from the US Census Bureau using the R package tidycensus [49]. The concentration
of cannabinoids in Federal seizures was taken from published
reports from the Drug Enforcement Agency [50, 51]. The main
cannabinoid of interest was state-level Δ8THC exposure.

Derived Data
Quintiles of substance use were calculated across the whole
period by dividing it into five equal intervals, with the lowest
quintile being designated as Quintile 1 and the highest quintile
denoted as Quintile 5. State-level cannabinoid exposure was estimated as the product of the amount of cannabis used in each state
last month and the concentration of that cannabinoid in Federal
seizures by methodology established previously [15, 16, 19, 52, 53].

Statistics
Data were processed in R Studio version 1.4.1717 based on R version 4.1.1 from the Comprehensive R Archive Network. Data were
manipulated using dplyr from the tidyverse suite [54]. Maps were
drawn using sf [55]. Graphs were drawn using ggplot2 also from
tidyverse [54], and multiple graphs were arranged using ggpubr
[56]. The ggrepel package was used to position labels on volcano
plots. Bivariate linear regression was conducted in Base R. Panel
multivariable regression was conducted using the plm package
using the two-way (simultaneous space–time) effect [57]. Overall or marginal effects of covariates in interactive multivariable
models were calculated using the margins package in units of
standard deviations of the dependent variable, which was the
defect-specific CA rate (CAR) [58]. Categorical analyses were conducted using the epiR package [59]. Multiple models for each CA
were considered simultaneously in a single analytical run using
the purrr package from tidyverse to facilitate recursive modelling
together with functions from the expected value (E-value), margins, broom [60, 61], epiR and dplyr packages. The analysis was
performed in October 2021. All t-tests were two-tailed. P < 0.05 was
considered significant.
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[15–18]. Indeed, all five chromosomal anomalies followed serially
by the CDC were recently noted to be elevated causally in association with THC and cannabigerol along with several common
cancers [19].
Cannabidiol and cannabichromene have been noted to be
directly toxic to the bases of DNA, causing mutagenic base oxidation, and to chromosomes, causing single- and double-stranded
breaks at low doses [20]. Cannabinol, cannabidiol and Δ9THC
were shown long ago to be toxic to chromosomes, inducing the
formation of minute fragments and ring and chain translocations [21, 22]. They also induce major structural damage to sperms
and the reproductive tract in both sexes [23, 24], and cannabis
smoke has been shown to induce a massive 20% oocyte loss with
just the first meiotic cell division [25]. Hence, there is evidence for
the genotoxic effects of multiple cannabinoids. However, rather
than this being a particular property of individual cannabinoids,
it was shown long ago that the genotoxic moiety lay in the olivetol nucleus, which forms the core structure of the C-ring of the
cannabinoid class [26, 27].
Many in vitro studies clearly demonstrate that cannabinoid cellular toxicity exponentiates in the micromolar dose range [28–32]
and it accumulates in fat stores, particularly where they are
held behind membrane tight junctions as in the blood–brain barrier and the blood–testis barrier [33]. Moreover, this exponential dose-related cumulative toxicity has since been confirmed
in epidemiological studies [9, 14, 15]. This implies that far from
merely academic interest, these in vitro dose-ranging effects carry
far-reaching implications for patterns of disease and genomic
dysfunction at the level of population health.
Prenatal cannabis exposure has also been shown to have a
marked effect on the epigenome through large-scale and heritable perturbation of DNA methylation, an effect expressed in
increased susceptibility to addictive behaviours in later (rodent)
life with analogous changes in the human sperm methylome
[34–40]. Δ9THC has also been shown to suppress histone synthesis and acetylation and phosphorylation [41–43]. Reduced histone formation necessarily opens the chromatin for unregulated
transcription and is known to predispose to oncogenesis.
Clearly, the prospect of multigeneration inheritance of genotoxic and epigenotoxic mutational burdens is a very serious health
issue. However, cancer and CAs are together relatively rare health
outcomes. Arguably, most concerning of all is the recent formal demonstration by a group from Harvard Medical School that
the epigenome directly controls the expression of ageing gene
networks and cassettes and can bidirectionally and powerfully
impact cellular age [44]. This implies that food chain contamination by cannabinoids [45] can lead to subtle and lasting effects
which are disadvantageous to the health of whole populations and
their progeny. The pro-ageing effects of cannabis on biological age
in humans have previously been demonstrated [46].
Altogether, these several features make a formal investigation
of the potential genotoxicity/epigenotoxicity of the novel artificial
cannabinoid Δ8THC a high priority. The present paper engages
this research in CAs of childhood. The hypothesis that Δ8THC
exposure might be linked with CAs of childhood was formulated
prior to study commencement.

Causal inference

Results
Table S1 provides an overview of the CAs studied and median
household income and ethnicity covariate details. In total, 57
CAs were studied after adjusting facial and limb anomalies as
described in the Methods section. An important determinant of
the total CAR is the early termination for anomaly (ETOPFA) rate,
which varies by CA. Table S2 shows a selection of surveys of
ETOPFA rates for selected CAs from Australian and American
series [64–71]. The final ETOPFA rate is the composite value shown
in the right-hand column. It is likely that the ETOPFA rate has
changed over time. The only detailed longitudinal time series we
were able to locate is from the Western Australian Registry of
Developmental Anomalies for Down’s syndrome, which is shown
in Table S3 and runs from 1980 to 2015. The fraction of maximal
termination rate in the right-hand column was applied to all CAs
by year as an estimate of the temporal effect of rising ETOPFA
rates in order to calculate estimates of the ETOPFA-corrected CARs
(ETOPFACARs).
Figure S1 shows the concentration of various cannabinoids
reported in assays of Federal seizures across the study period.
Many cannabinoids including Δ8THC are noted to have risen.
Figure S2 represents map-graphically estimates of the Δ8THC
exposures across the country in this period.

Continuous Bivariate Analysis
Figure S3 shows the unadjusted rate of the various anomalies as
a function of tobacco exposure for the raw reported CARs. Many
CAs in the first three lines of this graph appear to demonstrate a
positive relationship with tobacco exposure. When the exercise is
repeated for AUD exposure, some of the CAs in the first line appear
to be positively related (Fig. S4). When the exercise is repeated
for Δ9THC, most of the CAs in the first five lines are noted to
be positively related (Fig. S5). When this is done for Δ8THC, the
CAs in the first three to four lines demonstrate positive regression
slopes (Fig. S6). When this is done for analgesics and cocaine exposures, the results are more modest, with 3.5 and 1.5 lines of CAs
demonstrating positive regression slopes (Figs S7 and S8).
The regression results of these efigures are summarized formally by recursive linear models and are presented for these
substances and others in Tables S4–S11. These tables show that
for cigarettes, AUD, cannabis, Δ9THC, Δ8THC, cannabidiol, analgesics and cocaine, 14, 6, 29, 31, 23, 11, 13 and 8 CAs demonstrated
elevated minimum E-values (mEVs), respectively.
This exercise is then repeated for the ETOPFACARs. These
results are presented graphically in Figs S9 and S10, Figs 1 and 2,
Figs S11 and S12 and Tables S12–S17 for cigarettes, AUD, Δ9THC,
Δ8THC, analgesics and cocaine, respectively. The results show

Categorical Bivariate Analysis
Substance exposure metrics can be quantized into categorical
quintiles of exposure in order to calculate key epidemiological
indices, such as relative risk (RR), attributable fraction among
the exposed (AFE) and population attributable risk (PAR). Panelled
boxplots representing comparisons of the extreme quintiles are
shown for tobacco, AUD, cannabis, Δ9THC, Δ8THC, analgesics and
cocaine in Figs S17–S22 and Fig. 4, respectively. Reports of the RR,
AFE, PAR and chi-squared tests including P-values and mEVs are
shown in tabular form in Tables S18–S23 where 18, 3, 34, 41, 17
and 7 CAs are found to occur with increased mEV in the highest
quintiles.
These results are summarized across substances in Table S24.
This table shows the number of CAs having elevated RRs, AFEs and
PARs and their lower bounds, along with summary metrics for the
total of the negative P-value exponents, a count of the number of
CAs with elevated mEVs and the total of the mEVs.
Six of these metrics are summarized in Fig. S23. It is noted
that across all the domains examined, Δ8THC consistently outperforms other substance exposures and appears at the extreme
right-hand end of each of the six graphs.
These results from categorical bivariate analysis therefore confirm the results obtained in continuous bivariate analysis, indicating that Δ8THC and Δ9THC are implicated with numerically more
CAs and with a much higher effect size than traditional teratogens
such as tobacco and alcohol.

Multivariable Panel Regression
Panel regression was the multivariable technique chosen to
adjust the above bivariate results for common socio-demographic
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All panel models were inverse probability weighted for Δ8THC
exposure across all other substance exposures, a methodology
which has the effect of evening out substance exposures across
all groups, creating a pseudorandomized paradigm from which
formal causal relationships can properly be assessed. E-values
were also calculated for bivariate and multivariable regression
equations using the R package E-value [62]. This value shows the
degree of association required of some hypothetical unmeasured
confounder variable with both the exposure of interest and the
outcome of concern in order to explain away the apparently causal
nature of the observed association. Inverse probability weights
were calculated with the R package ipw and were utilized in all
multivariable panel models [63].

that each substance is associated with 12, 3, 36, 33, 13 and 6
ETOPFACARs, respectively. This result makes it clear that the associations of ETOPFACARs with cannabinoids are much stronger
than for other widely recognized clinical teratogens.
Since the above tables present rather a lot of information, these
data for significant CAs are summarized in volcano plots designed
by analogy with plots common in the genomic and epigenomic
literature for charting the significance level of gene expression
changes against its fold change. A similar exercise has been done
here for significantly positively related CAs with the charting
of the (negative) log of the P-value (on the y-axis) against the
mEV (on the x-axis). Figure S13 performs this function for the 12
tobacco-related ETOPFACAR CAs identified in Table S12. Similarly
Fig. S14 does this for three AUD-related ETOPFACARs identified in
Table S13.
Figure S15 is a similar volcano plot for the 36 ETOPFACARs
noted to be linked with Δ9THC exposure. Figure 3 performs a
similar function for the 33 ETOPFACARs linked with Δ8THC. Several features in this figure are noteworthy. There are clearly many
more CAs on this plot than for both cigarettes and AUD combined.
Moreover, the scale of this plot is much greater than that of the earlier plots with log mEVs of >200 and negative log P-values of >60.
Four of the five chromosomal anomalies (trisomies 21, 18 and 13
and Turner syndrome) are in or near the top-right quadrant. The
fifth chromosomal anomaly also features on this plot (Deletion
22aq11.2), which although it has a P-value of 0.0034 and mEV of
5.68 × 1014 (Table S15) features lower in the plot.
Finally, 11 ETOPFACARs which are similarly raised for
cannabidiol are shown in Fig. S16. Again the magnitude of the represented effects is much greater for cannabidiol than for tobacco
or alcohol.

Figure 1: Trends of ETOPFA-corrected CARs as a function of Δ9THC exposure

Downloaded from https://academic.oup.com/eep/article/8/1/dvac012/6586812 by Serials Acquisitions Edith Cowan University, Library-Level 2 user on 16 September 2022

Figure 2: Trends of ETOPFA-corrected CARs as a function of Δ8THC exposure
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Figure 3: Volcano plot of negative log of P-value against log of minimal E-value for CAs significantly positively related to Δ8THC on bivariate testing
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Figure 4: Categorical panelled boxplot contrasting the ETOPFA-adjusted CAR by highest and lowest exposure quintiles of Δ8THC exposure
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Table 1: Summary table by system—additive multivariable panel model
Total Number
of Anomalies in
System

% of Anomalies
in System

Mean Lower
Bound E-Value

Median Lower
Bound E-Value

Total of P-Value
Negative
Exponents

Total of
E-Value
Exponents

Chromosomal
Body wall
CVS
GUT
Limb
GIT
CNS
Face

5
3
15
4
2
4
3
3

5
3
19
6
3
7
6
7

100.0
100.0
78.9
66.7
66.7
57.1
50.0
42.9

2.85E + 46
8.78E + 28
1.90E + 21
1.68E + 27
1.50E + 28
7.08E + 40
7.00E + 23
4.46E + 32

2.85E + 46
8.78E + 28
1.90E + 21
1.68E + 27
1.50E + 28
7.08E + 40
7.00E + 23
4.46E + 32

55
18
78
34
7
24
11
17

233
82
404
86
45
131
59
79

covariates including other substances, ethnicity and median
household income. The substances studied were cigarettes, AUD,
Δ8THC, analgesics and cocaine. All models were inverse probability weighted to allow formal causal inferences to be drawn.
E-values were calculated in each case.

Additive Panel Model
Table S25 shows the 164 terms with positive and significant coefficients to emerge from additive panel modelling incorporating all
socio-demographic substance and income covariates. Table S26
extracts 39 terms for Δ8THC. Urological, cardiovascular, chromosomal and gastrointestinal anomalies feature prominently.
Table S27 summarizes these findings by covariate listed in
descending order of total mEV exponents. In this table, Δ8THC
is noted to have higher results across all domains including the
number of CAs implicated [39], mean mEV (2.789 × 10124 ), median
mEV (2.09 × 1027 ), total negative P-value exponents (244) and total
mEV exponents [1, 119].
These results are shown graphically in Fig. S24, where again
Δ8THC is noted to occupy the extreme right-hand position on all
four graphs for the number of implicated CAs, log of mean mEVs,
log of total mEVs and sum of total negative P-value exponents.
Table 1 shows these results analysed by organ systems and
listed in descending order of the total percentage of CAs in each
organ group. This list is headed by chromosomal and body wall
anomalies, each with 100% CAs affected. Cardiovascular, genitourinary, limb defects (66.7%) and gastrointestinal anomalies all
have in excess of 50% of their CAs listed. central nervous system
(CNS) and facial anomalies have 50% and 43% listed, respectively.
These results are shown graphically in Fig. 5, where again chromosomal, cardiovascular, limb, genitourinary and gastrointestinal
anomalies feature prominently.

Interactive Panel Model
A similar model including all covariates was considered incorporating a three-way interaction between cigarettes: AUD and
Δ8THC. It was also inverse probability weighted. Table S28 shows
the 126 terms with positive and significant coefficients to emerge
from this model. From this model, 13 terms including Δ8THC can
be extracted (Table S29). Five of these mention the same CA twice.
Extracting the most significant of these terms leaves the results
shown in Table 2, which lists eight CAs. The Table also lists various metrics for the overall or “marginal” effect of covariates at
the average of model covariates which is very useful for interactive models where different interactions may often result in
opposing signs of model terms. This parameter is known as the
average marginal effect (AME). In this case, it is measured in units

of the standard deviation of the CAR for each CA. Facial (including
holoprosencephaly), chromosomal, body wall, cardiovascular and
gastrointestinal syndromes feature in the list of CAs shown in
Table 2.
Table S28 may be summarized by covariate, as shown in
Table 3. This table is also listed in the descending order of total
mEV exponents. Here again, Δ8THC is noted to head the list of
mean, median and total mEV exponents. These results are shown
graphically in Figs 6 and 7. As judged by the marginal effect
(Fig. 7), Δ8THC holds a mostly mid-rank position amongst the
other covariates and demonstrates a lower degree of variability
(highest mean to SEM of AME, panel d).
When body systems are considered chromosomal, body wall
and CNS systems predominate (Table S30 and Fig. S25).

Interactive Panel Model at Two Temporal Lags
The above interactive model was again considered with all independent covariates lagged by 2 years. In this instance, 90 terms
with positive and significant coefficients emerged, as shown in
Table S31. It should be noted here that in R, the largest integer
which is routinely considered is 1.7 × 10307 so that numbers larger
than that are usually denoted as infinity. To make this analysable,
this infinite number has been replaced by its minimum exponent (307) in all summary indices. Δ8THC was mentioned in eight
of the terms mentioned in Table S31 (shown in Table S32) and
for each of the four anomalies identified duplicate entries were
recorded. When the most significant of these was retained (which
was Δ8THC itself in each case), the results shown in Table S34
were obtained. Interestingly, the percentage AME in each case
ranged from 2.1% to 10.5% SDs for each CA.
The results from Table S31 are summarized in Table S34, which
is again listed in the descending order of total mEV exponents.
Δ8THC is noted to have the highest position of median and total
mEVs and occupies a mid-position for the number of CAs implicated and the sum of the P-value exponents (Fig. S26). Δ8THC has
a lower position for summary indices of AMEs and a smaller range
of variability (Fig. S27).
Table S31 may also be summarized by body organ systems
for Δ8THC. These results are shown in tabular form in Table
S35 and graphically in Fig. S28. Once again limb, genitourinary, cardiovascular and gastrointestinal systems feature in these
graphs of percentage of anomalies affects, mEV exponents,
P-value exponents and total AME.

Interactive Panel Model at Four Temporal Lags
This interactive model was again investigated with all independent covariates lagged by 4 years. In this instance, 78 terms
with positive and significant regression coefficients were obtained
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System

Number of
Anomalies
Implicated

which are presented in Table S36. In 18 cases terms included
Δ8THC (Table S37) and when the most significant were selected
out, nine terms remained (Table S38). Here, the percentage AME
ranged up to 21.7% for biliary atresia.
Table S36 may be summarized by covariate as shown in Table
S39, which is again listed in descending order of total mEV exponent. Once again, Δ8THC heads this list across several columns.
As shown in Fig. S29, Δ8THC is at the extreme right-hand position for the number of anomalies implicated and the median
and total mEV exponents. At four lags its marginal effect wanes
(Fig. S30).
When the terms including Δ8THC from Table S36 are summarized by the system, the highest number of affected anomalies
occurs in the limb, genitourinary and face systems, the highest
mEVs are in the cardiovascular and genitourinary systems and the
most affected systems are the gastrointestinal and cardiovascular
systems (Table S40 and Fig. S31).

in an additive multivariable model. Investigation in interactive
models lagged to 0, 2 and 4 years reduced the numbers of
CAs implicated but greatly increased the mEVs often to infinity
(Table 2; Tables S33 and S38). Importantly since all multivariable
models were inverse probability weighted, this analytical context
allows causal inferences to be drawn from these results. Together,
the use of inverse probability weighting and extremely elevated
mEVs indicates that groups are broadly comparable and that
uncontrolled confounding is effectively excluded on quantitative
criteria.
Amongst continuous bivariate linear models corrected for estimates of ETOPFAs, the number of CAs was Δ9THC > Δ8THC >
analgesics > tobacco > cocaine > AUD with 36, 33, 13, 12, 6 and 3 of
57 CAs affected (Tables S18–S23). In additive fully adjusted inverse
probability-weighted panel models, the number of CAs implicated
was Δ8THC > cocaine = cigarettes > analgesics > AUD > with 39, 10,
10, 12 and 3 anomalies affected (Table S27).

Discussion

Interpretation

Main Results

Our interpretation of these obviously serious results is both concerned and guarded. We are concerned that the effects demonstrated are significant and that a number of CAs along with most
organ systems are strongly implicated. We are concerned that the
effects we are seeing are reminiscent of genotoxic effects recently

The data show that Δ8THC is associated with more CAs than
tobacco and alcohol combined on bivariate analysis both before
and after correction for estimates of ETOPFAs and also on
categorical analysis. These changes were increased by adjustment
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Figure 5: Summary of numbers of affected anomalies and P- and E-values by organ system from additive multivariable panel model of Table S25: (a)
number of CAs affected, (b) percentage of affected anomalies in each organ system, (c) total of mEV exponents by the organ system and (d) total of
negative P-value exponents by the organ system
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Δ8THC
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Anotia/microtia

0.69

2.45

0.90

2.76
0.53
0.45

0.89
0.37

2.05
1.66

0.98
1.85

0.58

0.76

SD CAR

2.34

2.23

Mean
CAR

2192.900

2306.041
16 720.952

41 386.379

4227.152
15 896.251

21 348.588

25 618.243

Estimate

0.384
0.315
0.488

974.297

0.612

0.541
0.294

0.429

0.511

Model
SD

1152.334
7689.631

15 218.314

1813.896
5238.978

7648.960

9089.476

Std.Error

2.251

2.001
2.174

2.720

2.330
3.034

2.791

2.818

TStatistic

Number of
Anomalies

9
15
12
15
11
12
17
14
10
17
4

Covariate

Δ8THC
Cigarettes
AUD
NHPI
Cocaine
Analgesics
AIAN
Caucasian
African
Hispanic
Income

10
27
16
36
39
29
55
35
24
106
7

Total of Negative P-Value
Exponents
2216
1946
1391
200
159
75
32
7
0
0
0

Total of mEV
exponents
246.22
129.73
115.92
13.33
14.45
6.25
1.88
0.5
0
0
0

Mean mEV
exponents
307
21
32.5
5
12
7.5
2
0.5
0
0
0

Median mEV
exponents

0.311

0.049
0.236

0.201

0.239
0.066

0.034

0.275

Adj.R2

0.39
0.16
−0.18
0.34
0.26
0.23
0.24
0.52
0.36
0.47
0.29

Mean AME

Table 3: Summary table for key parameters from interactive panel model of Table S28

Note that the units for the AME are standard deviations of the applicable CA.

Single ventricle
Small intestinal
atresia/stenosis
Trisomy 13

Atrioventricular
septal defect
Craniosynostosis
Diaphragmatic
hernia
Holoprosencephaly

Term

Defect
0.618
0.407
0.329
0.281
0.317
0.504
0.370
0.381

Δ8THC
Δ8THC
Δ8THC
Δ8THC
Δ8THC
Δ8THC
Δ8THC
Δ8THC

0.38
0.05
−0.07
0.29
0.23
0.2
0.22
0.43
0.37
0.39
0.28

0.04
0.1
0.07
0.06
0.04
0.05
0.03
0.07
0.06
0.07
0.06

0.222

0.320
0.233

0.023

−0.077
0.185

0.267

0.452

3.55
2.45
−2.21
5.17
2.89
2.72
4.1
7.25
3.6
7.97
1.18

0.540

0.688
0.508

0.611

0.734
0.377

0.546

0.785

AME Upper
Bound

9.75
1.6
−2.57
5.67
6.5
4.6
8
7.43
6
6.71
4.83

Mean to SEM
of AME Ratio

AME Lower
Bound

Total AME

2.76E–06

7.85E–08
1.29E–07

0.034346152

0.112328064
9.27E–09

1.08E–08

3.25E–13

P-Value of
AME

SEM of AME

AME

Covariate

Median AME

0.025

0.047
0.031

0.007

0.022
0.003

0.006

0.005

P-Value

0.35
0.06
−0.25
0.28
0.22
0.18
0.21
0.45
0.3
0.4
0.23

AME Lower
Bound

Infinity

Infinity
Infinity

Infinity

Infinity
Infinity

Infinity

Infinity

E-Value
Estimate

0.43
0.26
−0.11
0.4
0.3
0.28
0.27
0.59
0.42
0.54
0.35

AME Upper
Bound

Infinity

6.34E + 53
Infinity

Infinity

Infinity
Infinity

Infinity

Infinity

E-Value Lower
Bound

Table 2: Summary table for significant anomalies with positive coefficients from interactive multivariable panel model P- and E-values, AME and percent AMEs from Table S28
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described for cannabis and other cannabinoids and that are consistent with earlier cellular studies [20, 72, 73], the effect appears
to be a class effect implicating many cannabinoids [26, 27, 74].
We are concerned that much experimental and epidemiological
evidence points towards a clear threshold effect beyond which
exponential effects become commonplace [28–32]. And we are
concerned that Δ8THC marketing is being aggressively pursued
despite its class membership in a group of well-established genotoxic compounds. We are also very concerned that the quantitative criteria of causality are clearly fulfilled by the present findings.
Having said that the concentrations of Δ8THC in the samples analysed from Federal seizures during the period of this
study were very low at about 0.1% of the population (Fig. S1).
It thus seems mechanistically implausible to us that so low a
population exposure could be driving birth anomaly patterns
generally across the whole population. As Δ8THC generally occurs
with other cannabinoids, it may be a marker for cannabinoid
genotoxicity more broadly defined. Or perhaps the manufacturing processes that are used to generate it (strong acid, heating, etc.) also transform other cannabinoids, and Δ8THC is a
marker for these products. More research will be required on these
points. In this respect, therefore, our interpretation must remain
guarded.
However, it is also clear that secular cannabinoid trends have
moved a long way from 2014 and the penetration of this genotoxin
into the community may now be much more significant, possibly
even to the point where population effects might become feasible. For these reasons, it seems to us that further research into

these issues is urgently required both in epidemiology and in laboratory studies of Δ8THC- and cannabinoid-related genotoxicity
generally.
It is of interest that the findings in the present study contrast with those in many others which have not demonstrated a
link between cannabinoid exposure and significant CAs [75–79].
Most such studies used much smaller samples and generally different methodologies including inpatient samples and self-report
questionnaires. Some studies, for example, found a lack of association with gastroschisis [80], but it is clear from CDC–NBDPN
studies [81] and many other reports including some from the
same authors [8] and careful multivariate regression studies [82]
that gastroschisis is indeed linked to cannabis use [8, 82–87].
Similarly, some studies have not demonstrated a link between
Ebstein’s anomaly and cannabis use [88], but reviews from the
American Academy of Pediatrics and the American Heart Association have noted that it is indeed associated [89]. Therefore,
a certain amount of disagreement in the literature seems not
unusual.
It may be that the use of large national samples in the present
study provides a more sensitive study methodology for these
rare anomalies, particularly in an epidemiological context where
cannabis use was formerly at a relatively low level. We also note
the close concordance of the present results with recently published results from Europe, which similarly identified over 80 CAs
as being linked with various metrics of cannabis exposure [90].
As noted in the Introduction section, it is not unusual in large
regional or national studies to find many CAs linked with cannabis
exposure [8–13, 19, 53, 91].
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Figure 6: Summary of numbers of affected anomalies and P- and E-values by covariate from interactive multivariable panel model summarized in
Table S28: (a) number of significant positive anomalies by covariate, (b) median mEV by covariate, (c) log of total mEV exponents and (d) log (base 10)
of sum of negative P-value exponents

Causal Inference
It is of interest to consider how the present findings address
the nine hallmarks of causality set out by Hill [92]. The findings
reported herein demonstrate the strength of association, specificity to cannabinoids and not other substances, share appropriate
temporality, are coherent with known data, are biologically plausible, demonstrate an appropriate dose–response curve and are consistent with experimental findings. As this is the first such report,
it has not been replicated elsewhere and so cannot demonstrate
consistency amongst studies.
One of the major pitfalls of observational studies is that the
study groups may not be comparable. This aberration is corrected by the use of inverse probability weighting, which is the
adjustment of choice for causally relevant modelling.
Another major hypothetical concern is that some unmeasured
extraneous confounder covariate might exist, which explains
away an apparently causal effect. However, such covariates cannot simply be fantasized. The E-value defines the quantitative
correlation required of this unknown confounder covariate with
both the exposure of concern and the outcome of interest in
order to obviate the reported association. The usual mEV required
for reporting causal relationships is 1.25 [93]. The E-value for
the tobacco–lung cancer relationship is 9, which is regarded as
high [94]. Clearly, our study where inverse probability-adjusted
multivariable mEVs were infinite reports unusually high and in

fact prohibitive E-values and therefore excludes unmeasured confounding on quantitative criteria.

Mechanisms
Consideration of the basic cellular mechanisms which might
underpin the observed epidemiological findings is central to any
consideration of a possible causal effect. This subject has been
reviewed elsewhere [33, 39, 95]. Δ8THC is known to interfere with
the synthesis of DNA, RNA and proteins [96–100] and thus necessarily interferes with nuclear and DNA physiology and cell growth
like other cannabinoids [28, 101, 102].
Importantly, Δ8THC binds the type 1 cannabinoid receptor
[2, 99] and inhibits mitochondrial activity [103–107]. Mitochondria are in close communication with the cell nucleus to which
they supply ATP and numerous small molecular substrates for
epigenetic reactions and DNA maintenance. Mitochondria also
maintain close indirect communication with the nucleus through
several small-molecule shuttles [108]. Hence, the disruption of
mitochondria directly and indirectly perturbs and destabilizes
genomic maintenance and normal epigenomic regulation.
The epigenome was recently shown to regulate a stunning
array of fundamental cell functions including brain development [109], neuronal specification [109], neural network formation [110], learning [111], neocortical expansion [112, 113], glutamatergic neuronal specification [112] and long-term immune
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Figure 7: Summary of AMEs by covariate from the interactive panel model summarized in Table S28. (a) Mean AME, (b) median AME, (c) total AME and
(d) ratio of the mean to the standard error of the mean AME as a measure of AME variability by covariate

Generalizability
Since this report is based on some of the best available data on this
subject in the world, given the very strong effect sizes reported,
given its detailed and comprehensive inclusion of the techniques
of causal inference (inverse probability weighting and E-values)
at many points and the consequent demonstration of putatively
casual relationships, it seems to us that these results are likely to
be widely generalizable wherever data of sufficient quality exist
to investigate these relationships. However, given that this is an
initial report, we are keen to see these results replicated elsewhere geographically and also in a more up-to-date temporal
context.

Strengths and Limitations
This study has a number of strengths relating to data inputs
including the use of a large national registry population-based
database of CAs, the use of a large nationally representative sample of drug use and exposure and the use of cannabinoid exposure
data from a major federally contracted analytical laboratory. It
has several strengths relating to data analysis including the use of
simultaneous multiple model investigation, the use of the quantitative tools of causal inference, particularly inverse probability

weighting and E-values, and the use of multi-panelled graphs
and maps for broad-ranging data visualization. Study weaknesses
include the unavailability of solid data for ETOPFA rates and the
unavailability of state-level cannabinoid concentration data. In
common with many epidemiological studies, individual participant exposure data were not available to the present investigators.
Also, we were not able to account for hereditary factors which
might apply to anomalies such as orofacial clefts and neural
tube defects, nutritional factors, paternal factors (contributing to
factors such as non-disjunction) or the use of teratogenic medications taken during pregnancy (such as statins, warfarin, valproate,
radiation, anticonvulsants and antidepressants).

Conclusion
This report documents that rising Δ8THC levels are closely associated with many CAs, particularly in the cardiovascular, central
nervous, limb, gastrointestinal, genitourinary and face systems
with high effect sizes and mEVs. Moreover, the results indicate
that causal relationships are possible. Given the low concentration of Δ8THC in community samples, the present results do
not exclude the possibility that Δ8THC is a marker for cannabinoids generally or another more toxic cannabinoid or combination
thereof. The results are consistent with genotoxic effects reported
for several other cannabinoids, and together these data indicate
that genotoxicity is likely a class effect extending to many compounds in the cannabinoid class. Whilst the key quantitative
metrics of formal causal inference are amply fulfilled by these
results, we are keen to see these studies replicated elsewhere
and in a more contemporaneous temporal context before formal
causal attribution is assigned. Clearly, more laboratory research
is required on Δ8THC genotoxicity, epigenotoxicity and embryonal and developmental toxicity. Meanwhile, we feel that these
results clearly raise a high index of suspicion implicating Δ8THC
along with many other cannabinoids as significantly genotoxic
compounds. Of particular concern is that many cannabinoids
demonstrate prominent threshold effects in the micromolar range
beyond which genotoxicity, mitochondriopathy and epigenotoxicity exponentiate [28–32]. The presence of this threshold effect in
the context of rapidly rising community penetration of a genotoxic agent is a grave concern indeed. We therefore feel that this
initial report is a powerful stimulus to further research on Δ8THC
in the laboratory, in the clinic and amongst epidemiological investigators. Whilst further work is awaited, it would seem prudent
and precautionary to tightly control community penetration and
marketing of Δ8THC in line with restrictive policies universally
imposed on other compounds with potently genotoxic effects. The
very serious intergenerational implications of the present findings
for the health of subsequent generations across multiple major
body systems are of great concern indeed.

Supplementary data
Supplementary data are available at EnvEpig online.

Data availability
Input data and the major datasets employed including several scripts of original R-Code have been made publicly available through the Mendeley Data repository at doi: 10.17632/fbdcrhgvbj.1. Supplementary data files list additional result output.
Conflict of interest statement. None declared.
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and metabolic memory held on lymphoid stem cells’ epigenome
[114, 115].
It is also of relevance to observe that many cannabinoids interfere with key body morphogens including sonic hedgehog [32],
retinoic acid [116–118], bone morphogenetic proteins [119–121],
fibroblast growth factor [122] and many others.
For example, it is easy to see how cannabinoid exposure during
a critical window of gestation at Days 24–26 could disrupt limb bud
formation or digital development or, at different times, formation
of the facial forebrain or central cardiovascular structures since
all are dependent on sonic hedgehog signalling [123].
It has recently been formally demonstrated in Europe that the
continent is undergoing a triple convergence of rising prevalence
of cannabis use, increased intensity of cannabis daily use and
increased cannabis potency [124, 125]. The same is true in USA
and in many other places [15, 16, 19, 51, 52, 126].
Pathophysiologically, another very serious and extremely concerning convergence is also occurring as the exponential dose–
response effects of cannabinoids [28–32], their entry into the food
chain without consumer consent, damage to the genetic material at chromosomal, genetic and epigenomic–mitochondriopathic
levels, their effects on CAs, cancerogenesis and population
genomic ageing and multigenerational impacts increasingly come
to bear.
The documentation in the present report that all the chromosomal anomalies affecting chromosomes 13, 18, 21, 22 and X
are elevated in association with Δ8THC exposure is of particular
concern, particularly in the light of previous findings implicating
cannabinoids with elevated rates of acute lymphoid leukaemia of
childhood [15], which entails major damage to chromosome 9 and
testicular cancer [52] and which further entails damage to chromosome 12. Together the length of these chromosomes comprises
585 megabases of the human genome or ∼19.5%. Clearly, these
findings directly implicate diverse cannabinoids in major human
genotoxicity at the hundred megabase scale.
Also concerningly it appears that as the major CA and cancer
databases lag behind current developments by several years, our
public health systems are presently ill-prepared to monitor and
track pertinent developments in real time.

Ethics. The study was given ethical approval from the University of
Western Australia Human Research Ethics Committee on 14 June
2018 No. RA/4/20/4627.
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